美多芭联合盐酸普拉克索治疗帕金森病临床研究.docVIP

美多芭联合盐酸普拉克索治疗帕金森病临床研究 　　[摘要]目的 探讨美多芭联合盐酸普拉克索对帕金森病患者的治疗效果。方法 选取2013年4月～2016年4月在我院就诊的124例帕金森病患者作为研究对象。按照随机数字法将其分为对照组（62例，采用美多芭治疗）和观察组（62例，采用美多芭联合盐酸普拉克索治疗）。比较两组患者的临床疗效、帕金森评分量表（UP-DRS）评分、生活质量量表（ADL）评分及不良反应发生情况。结果 治疗前，两组患者的UP-DRS评分比较，差异无统计学意义（P0.05）。治疗6周、12周后，观察组患者的UP-DRS评分均显著低于对照组，差异有统计学意义（P0.05）。结论 针对帕金森病患者，采用美多芭联合盐酸普拉克索治疗的效果显著，在提升治疗有效率同时未增加患者不良反应，值得推广。 　　[关键词]帕金森病；美多芭；盐酸普拉克索；治疗效果 　　[中图分类号] R749.1 [文献标识码] A [文章编号] 1674-4721（2017）12（b）-0125-03 　　[Abstract]Objective To investigate the therapeutic effect Madopar combined with Pramipexole Hydrochloride for the treatment of Parkinson′s disease.Methods Altogether 124 patients with Parkinson′s disease who were treated in our hospital from April 2013 to April 2016 were selected as the research objects and divided into control group （62 cases，treated with Madopar） and observation group （62 cases，treated with Madopar combined with Pramipexole Hydrochloride） according to the random number method.The treatment efficiency，Parkinson′s score scale （UP-DRS），quality of life scale （ADL） score and clinical adverse reactions were compared between the two groups.Results Before the treatment，the UP-DRS score of patients in two groups were compared，and the difference was not statistically significant （P0.05）.While in 6 weeks and 12 weeks after treatment，the observation group of patients with the UP-DRS scores were significantly lower than the control group，the differences were statistically significant （P0.05）.The ADL score of the patients in the observation group was significantly higher than that in the control group，and the difference was statistically significant （P0.05）.The total effective rate of treatment in the observation group was significantly higher than that in the control group，and the difference was statistically significant （P0.05）.Conclusion The therapeutic effect of Madopar combined with Pramipexole Hydrochloride for the treatment of Parkinson′s disease is significantly improved，and it is worth promoting to improve tre